GLP-1 agonists and throat symptoms

If you have been taking semaglutide or another GLP-1 receptor agonist and noticed a persistent cough, a sensation that something is stuck in your throat, or changes to your voice, you are not alone. A large retrospective study published in The Laryngoscope in August 2026 found statistically significant associations between GLP-1 agonist use and several laryngeal symptoms in obese adults^[1]. This article explains what the study found, what the proposed mechanism is, and what the findings mean in practical terms.

What the 2026 study found

Researchers analysed health data from 2016 to 2025 across US insurance records, comparing 617,296 adults who had received a GLP-1 receptor agonist prescription with approximately 3.5 million matched controls who had not^[1]. The study looked at whether patients on these medications were more likely to develop laryngeal symptoms, including chronic cough, a foreign body sensation in the throat (a hallmark of laryngopharyngeal reflux), and voice or resonance disorders.

The analysis found increased odds for three specific symptom categories: cough (odds ratio 1.46, p < 0.0001), foreign body sensation (odds ratio 1.41, p < 0.001), and voice and resonance disorders (odds ratio 1.19, p = 0.002)^[1]. In statistical terms, those are modest effect sizes, but the study authors noted that given the scale of GLP-1 use worldwide, even a small per-patient increase in risk could translate to a substantial number of affected individuals.

Not all agents in the class behaved the same way. Several specific drugs, including exenatide, liraglutide, semaglutide, dulaglutide, and lixisenatide, showed significant individual associations. Two agents, albiglutide and tirzepatide, did not show statistically significant associations with laryngeal symptoms in this dataset^[1]. The authors were cautious about drawing firm conclusions from these differences, as several factors, including prescribing frequency and patient population, vary across agents.

The probable mechanism: delayed gastric emptying and reflux

GLP-1 receptor agonists slow gastric motility as part of their mechanism of action: this contributes to satiety and reduced caloric intake. Pharmacovigilance data published in PLoS One in 2026 confirmed that semaglutide had the strongest association with impaired gastric emptying among all drug classes analysed, with a reporting odds ratio of 80.27 in the FDA Adverse Event Reporting System^[2]. When the stomach empties more slowly, stomach contents can reflux upward into the oesophagus and, from there, into the larynx and pharynx.

This is the pathway that connects GLP-1 use to laryngeal symptoms. Laryngopharyngeal reflux (LPR) occurs when stomach acid reaches the larynx, and its characteristic presentation includes chronic throat-clearing, a globus sensation (the feeling of a lump in the throat), hoarseness, and cough. A 2026 review in Annals of Otology, Rhinology and Laryngology noted that delayed gastric emptying from GLP-1 agonists may contribute to reflux, chronic cough, and aspiration risk in surgical patients^[3]. A gastroenterology-focused review similarly identified GLP-1-related gastric slowing as a clinically relevant factor for reflux outcomes^[4].

Additional mechanisms have been proposed. Weight loss reduces the mechanical pressure on the lower oesophageal sphincter, which can improve reflux in the long run. At the same time, significant and rapid weight loss can alter soft-tissue anatomy around the larynx and pharynx in ways that are not fully characterised. Reduced salivation has also been noted anecdotally but has not been studied systematically in this context.

What this does and does not tell us

Observational studies of this scale can identify associations, but they cannot establish cause and effect. People taking GLP-1 agonists are, by definition, a population with obesity, which is itself a risk factor for reflux and laryngeal symptoms. The study authors attempted to control for confounders, but residual confounding in retrospective insurance-claims analyses is a known limitation^[1]. It is also not clear from the data whether the laryngeal symptoms were transient (consistent with the early nausea and GI distress that commonly resolves within weeks of starting these drugs) or persistent.

The tirzepatide finding, where no significant association was detected, is worth noting. Tirzepatide is a dual GIP and GLP-1 receptor agonist with a different pharmacological profile from the pure GLP-1 agents. Whether that pharmacological difference explains a different laryngeal-symptom profile, or whether the finding reflects the shorter time tirzepatide has been in wide use (and therefore less surveillance data), is an open question the current data cannot resolve.

What to do if you are experiencing these symptoms

If you are on a GLP-1 receptor agonist and have developed a persistent cough, throat discomfort, or voice changes, the appropriate first step is to raise this with the clinician who prescribed your medication. These symptoms could reflect laryngopharyngeal reflux that is manageable, but they can also have other causes that a clinician can assess, including post-nasal drip, allergies, or structural issues. Do not stop or adjust your prescribed medication without clinical guidance.

Standard approaches to managing reflux-related laryngeal symptoms include dietary changes (avoiding late meals, reducing caffeine and acidic foods), positional adjustments (head elevation during sleep), and, when appropriate, pharmacological management of reflux. Whether any of these interventions specifically address GLP-1-associated laryngeal symptoms has not been tested in a controlled trial.

The bottom line

A well-powered retrospective study has found a modest but statistically significant association between several GLP-1 receptor agonists and laryngeal symptoms, including cough, foreign body sensation, and voice changes. The most plausible explanation is that drug-induced delayed gastric emptying promotes laryngopharyngeal reflux. The findings are observational and do not alter the well-established benefit-risk profile of approved GLP-1 agents for their licensed indications, but they add to a growing body of evidence that clinicians and patients should be aware of. If you are experiencing throat or voice symptoms while on one of these medications, speak to your prescriber.^[1]

This article is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making any decisions about your medication or treatment.